Amcad Biomed (ROCO:4188) Other Current Liabilities: NT$2.08 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4188 Amcad Biomed Corp ROCO:4188
50 GF Score
Price NT$16.15
GF Value NT$9.65
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Amcad Biomed Other Current Liabilities?

Amcad Biomed ROCO:4188 +0.62% 50 Other Current Liabilities is NT$2.08 Mil as of Jun. 2026. GuruFocus rates ROCO:4188 with a GF Score™ of 50/100 and a GF Value™ of NT$9.65 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Amcad Biomed's other current liabilities for the quarter that ended in Jun. 2026 was NT$2.08 Mil.

Amcad Biomed's quarterly other current liabilities increased from Dec. 2025 (NT$1.77 Mil) to Mar. 2026 (NT$2.08 Mil) and increased from Mar. 2026 (NT$2.08 Mil) to Jun. 2026 (NT$2.08 Mil).

Amcad Biomed's annual other current liabilities declined from Dec. 2023 (NT$3.47 Mil) to Dec. 2024 (NT$1.82 Mil) and declined from Dec. 2024 (NT$1.82 Mil) to Dec. 2025 (NT$1.77 Mil).

Amcad Biomed Other Current Liabilities Related Terms

Amcad Biomed Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Amcad Biomed's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amcad Biomed Other Current Liabilities Chart

Amcad Biomed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.10 4.33 3.47 1.82 1.77

Amcad Biomed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.78 7.88 1.77 2.08 2.08
ROCO:4188
50GF Score
Amcad Biomed Corp ROCO:4188
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amcad Biomed Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of NT$2.08 Mil mean?
Amcad Biomed (ROCO:4188) has a Other Current Liabilities of NT$2.08 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Amcad Biomed.
Is Amcad Biomed's Other Current Liabilities too high?
Amcad Biomed's current Other Current Liabilities is NT$2.08 Mil. Overall, Amcad Biomed has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amcad Biomed's Other Current Liabilities compare to ABT and SYK?
Amcad Biomed's Other Current Liabilities of NT$2.08 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Devices & Instruments company?
A good Other Current Liabilities depends on the Medical Devices & Instruments industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Amcad Biomed. Amcad Biomed's current Other Current Liabilities is NT$2.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amcad Biomed stock overvalued right now?
Based on GuruFocus' analysis, Amcad Biomed (ROCO:4188) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$9.65, compared to a current price of NT$16.15 — trading 67.4% above its estimated fair value. The current Other Current Liabilities is NT$2.08 Mil. Amcad Biomed's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Amcad Biomed (ROCO:4188), the current Other Current Liabilities is NT$2.08 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amcad Biomed (ROCO:4188) Overvalued in 2026?

Based on GuruFocus' analysis, Amcad Biomed stock appears to be overvalued. The current stock price of NT$16.15 is trading 67.4% above its estimated GF Value™ of NT$9.65. GuruFocus considers Amcad Biomed to be Significantly Overvalued.

Key valuation signals for ROCO:4188:

  • Other Current Liabilities: NT$2.08 Mil
  • GF Value™: NT$9.65 vs. price of NT$16.15 (67.4% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4188 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amcad Biomed Business Description

Address Fuxing N. Road, No. 167, 5th Floor, Zhongshan District, Taipei, TWN, 104
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. Geographically, the company generates revenue from Taiwan, China, Europe, Asia (excluding Taiwan and China), and other countries, out of which the majority of the revenue is generated from Taiwan. The company has two segments: the Medical Diagnostic Software segment, which is responsible for the development and sales of smart medical imaging diagnostic software devices, and the Precision Medical Equipment segment, which is responsible for research, development, manufacturing, and sales of high-end ultrasonic probes. The company generates the majority of its revenue from the Precision Medical Equipment segment.
50GF Score

Get the complete analysis for ROCO:4188

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.15
Price
NT$9.65
GF Value